Novo Nordisk surprised many medical weight loss clinics, med spas, and providers by suing several medical spas, wellness clinics, and compounding pharmacies. The lawsuits accuse these businesses of false advertising, trademark infringement, and illegally selling compounded versions of the company’s branded diabetes and weight loss drugs, Ozempic and Wegovy. Novo Nordisk alleges that some defendants falsely claim compounded medications are the branded drugs.
I Don’t Want to be Sued; What Should I Do?
The FDA has approved the use of compounded semaglutide for so long as Ozempic and Wegovy remain on the FDA’s drug shortages list. The most important thing for providers and weight loss clinics to do is to stay in compliance with this FDA advisory. Stay compliant and avoid legal risks by following these guidelines:
- Follow FDA Guidance: The FDA permits compounded semaglutide as long as Ozempic and Wegovy remain on the FDA’s drug shortages list. Review the FDA advisory here: FDA Advisory on Semaglutide.
- Source Correctly: Obtain semaglutide only from reputable compounding pharmacies and ensure they use the base form of semaglutide, not salt forms.
- Communicate Honestly: Inform patients about the drug shortage and clarify that you use compounded semaglutide based on an agreement with your pharmacy.
- Advertise Accurately: Avoid false claims in your marketing. Do not reference brand names unless you are specifically providing those branded medications.
If you have any questions or concerns about your practice’s marketing or prescribing of semaglutide or similar drugs, please contact 1818 today. Our experienced attorneys can help you effectively navigate the weight loss clinic/ med spa process, protect your rights, and advocate for your best interests.
Call us at (312) 779-1818 or fill out our online contact form for further assistance and expert advice.
